Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy

Kidney Int. 2022 Mar;101(3):646-647. doi: 10.1016/j.kint.2021.12.019.

Authors

Coralien H Vink¹, Bram van Cranenbroek², Joost W van der Heijden³, Hans P J M Koenen², Jack F M Wetzels⁴

Affiliations

¹ Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: [email protected].
² Department of Immunology, Radboud University Medical Center, Nijmegen, the Netherlands.
³ Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands.
⁴ Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 35190038
DOI: 10.1016/j.kint.2021.12.019

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Autoantibodies
Drug Resistance*
Glomerulonephritis, Membranous* / drug therapy
Humans
Receptors, Phospholipase A2* / immunology

Substances

Antibodies, Monoclonal
Autoantibodies
Receptors, Phospholipase A2
daratumumab